Price: FREE for members and non-members
Session recorded on March 10, 2022
Speaker: Gailen Marshall, MD, PhD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
1. Understand the major indications for the use of systemic corticosteroids in patients with persistent asthma
2. Determine the relative risk of using SCS vs . more chronic alternative therapies in individual patients with asthma based upon risk factors
3. Describe the relative steroid sparing effects of alternative therapies such as biologics in patients with persistent asthma
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Gailen Marshall, MD, PhD, Speaker
Nothing to disclose.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance